Ideaya Biosciences cleared its own late-stage success benchmark for a rare eye cancer drug, and the company now plans to file for accelerated approval with FDA.
The benchmark matters. The rare eye cancer has few approved systemic treatment options, making any successful late-stage readout a commercially material event. Ideaya set an internal success threshold before the trial data was unblinded. Hitting that bar in the late-stage trial means the drug performed exactly as the company said it would need to, removing a key source of uncertainty for investors and setting up the next step: a regulatory filing.
The accelerated approval pathway lets FDA greenlight drugs for serious conditions based on surrogate endpoints reasonably likely to predict clinical benefit. It’s the fastest route to approval, and Ideaya now has late-stage data to take that path.
Full efficacy data and specific trial endpoints haven’t been released publicly. The company plans to file under the accelerated pathway.
— Sarah Chen